

UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS

AMGEN INC.,	)	
	)	
Plaintiff,	)	
	)	
v.	)	Civil Action No.: 05-12237 WGY
	)	
F. HOFFMANN-LA ROCHE	)	
LTD., a Swiss Company, ROCHE	)	
DIAGNOSTICS GmbH, a German	)	
Company and HOFFMANN LA ROCHE	)	
INC., a New Jersey Corporation,	)	
	)	
Defendants.	)	

PLAINTIFF AMGEN INC.'S MEMORANDUM IN SUPPORT OF ITS  
MOTION FOR RECONSIDERATION OR CLARIFICATION  
OF THE NOVEMBER 6, 2006 ORDER

Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Doc. 159

*November 30, 2006,*  
*The motion for reconsideration <sup>is denied.</sup> in clarification,*  
*the court makes the remarks noted below:*

TABLE OF CONTENTS

PAGE NO.

I. INTRODUCTION..... 1

II. THE COURT SHOULD RECONSIDER ITS ORDER ENDORSING A TWO-TIER PROTECTIVE ORDER..... 3

    A. A Two-Tier Protective Order Will Be Abused By Roche..... 4

    B. A Single-Tier Protective Order Adequately Protects Roche's Commercial Interests..... 6

    C. Amgen's In-House Counsel Should Have Access to Confidential Materials For This Litigation And Have Undertaken The Steps Necessary To Protect Roche's Confidential Information..... 7

III. IN THE ALTERNATIVE, AND IN ADDITION, AMGEN MOVES FOR CLARIFICATION OF THE COURT'S NOVEMBER 6, 2006 ORDER. .... 11

    (A) If A Two-Tier Protective Order Is Adopted In This Case, It Should Include Amgen's Proposed Definitions For Those Tiers..... 11

    (B) Amgen Seeks the Court's Clarification on In-House Counsel's Access to the BLA and INDs. .... 13

    (C) Roche's Proposal Also Places Unreasonable Restrictions on the Access to and Use of its BLA and INDs. .... 14

        1. The Parties' Treatment of the BLA and INDs in the ITC Proceeding Places Unreasonable Restrictions on the Access and Use of Such Documents Without Justification..... 15

        2. Roche Has Not Fulfilled its Obligation to Produce Fully Searchable or Complete Copies of its BLA and INDs. .... 16

    (D) Roche's Proposal Regarding the Filing of Confidential Information Is Unworkable. .... 18

    (E) Roche's Proposal Places Unwarranted Restrictions on the Definition of Experts and Consultants and is Unnecessary in Light of Other Provisions in the Protective Order. .... 18

CONCLUSION ..... 20

*no ordered in house counsel of Amgen may have access to BLA and INDs*

*denied - this is a discovery issue, not appropriate for clarification*

*no documents shall be filed in court under seal absent allowance of a particularized motion to seal which would be allowed only if the filing would reveal a trade secret. This litigation is public.*

*this dispute is not amenable to resolution on a motion for clarification.*

*William A. Young, District Judge*